Search

Newsletter image

Subscribe to the Newsletter

Join 10k+ people to get notified about new posts, news and tips.

Do not worry we don't spam!

GDPR Compliance

We use cookies to ensure you get the best experience on our website. By continuing to use our site, you accept our use of cookies, Privacy Policy, and Terms of Service.

Trump govt to end support for vaccine-aid organization, GAVI

Published on March 26, 2025 at 08:03 PM

President Donald Trump's administration plans to end the United States’ financial support for Global Alliance for Vaccines and Immunization, GAVI.

GAVI, an international organization, has helped purchase critical vaccines for children in developing countries, saving millions of lives over the past quarter century.

The New York Times reports that the administration decided only to continue some key grants for medications to treat HIV and tuberculosis, and food aid to countries facing civil wars and natural disasters.

According to the reports, the decisions were included in a 281-page spreadsheet that the United States Agency for International Development, USAID, sent to Congress Monday night.

The document listed the foreign aid projects USAID plans to continue and to terminate.

The media outlet reports that the cover letter details the skeletal remains of USAID after the cuts, with most of its funding eliminated, and only 869 of more than 6,000 employees still on active duty.

The letter said that the Trump's administration decided to continue 898 USAID awards and to end 5,341.

The remaining programs are now said to be worth up to $78 billion. However, only $8.3 billion of that is unobligated funds — money still available to disburse.

The figure suggests a massive reduction in the $40 billion that USAID used to spend annually.

Prev Article

We must root out bad actors’ — Cardoso on Naira exchange rate against dollar

Next Article

‘I can’t wait’ – Gary Neville buzzing as Man Utd legend starts new job that has nothing to do with football

Related to this topic:

Comments (0):

Be the first to write a comment.

Post Comment

Your email address will not be published. Required fields are marked *